A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7325 When Given in Multiple Ascending Oral Doses in Healthy Male and Healthy Female Subjects of Non-Child Bearing Potential
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2010
At a glance
- Drugs AZD 7325 (Primary)
- Indications Anxiety disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Dec 2010 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
- 07 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jun 2008 New trial record.